04:55 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Eiger discontinues ubenimex for PAH

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) discontinued development of ubenimex to treat pulmonary arterial hypertension (PAH). The company made the decision after the product missed the primary endpoint in the Phase II LIBERTY trial in the indication. Eiger...
19:51 , Jan 16, 2018 |  BC Extra  |  Clinical News

Phase II PAH readout sinks Eiger shares

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) lost $7.90 (49%) to $8.10 Tuesday after discontinuing development of ubenimex to treat pulmonary arterial hypertension. The company made the decision after the product missed the primary endpoint in the Phase...
19:10 , May 19, 2017 |  BC Week In Review  |  Clinical News

Eiger completes enrollment in Phase II to treat PAH

Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) completed enrollment of 61 patients with pulmonary arterial hypertension (PAH) in the North American Phase II LIBERTY trial evaluating Bestatin ubenimex plus standard of care (SOC). Patients in the double-blind, placebo-controlled...
21:44 , Feb 1, 2017 |  BC Week In Review  |  Clinical News

Bestatin: LIBERTY2 extension study started

Eiger began the open-label LIBERTY2 extension study of oral Bestatin for ≥24 weeks in about 45 patients who completed the double-blind, placebo-controlled, North American Phase II LIBERTY trial, which is evaluating thrice-daily 150 mg Bestatin...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

Bestatin ubenimex: Phase II started

Eiger began the double-blind, placebo-controlled, U.S. Phase II ULTRA trial to evaluate thrice-daily 150 mg oral Bestatin ubenimex for 24 weeks in about 40 patients. In 2015, Nippon granted Eiger rights to develop Bestatin for...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

Nippon Kayaku, Eiger deal

Nippon granted Eiger rights to develop Bestatin ubenimex for pulmonary arterial hypertension (PAH) and inflammatory diseases that involve leukotriene B4 (LTB4). Nippon markets Bestatin in Japan as an adjunct to chemotherapy agents for...
08:00 , Dec 3, 2015 |  BC Innovations  |  Targets & Mechanisms

The two faces of LTA4H

Although the enzyme LTA4H has long been considered a driver of inflammatory diseases, companies have yet to create an inhibitor that succeeds in the clinic beyond Phase II. That could be due to a secondary,...
01:56 , Nov 20, 2015 |  BC Extra  |  Company News

Eiger reverse-merges with Celladon

Eiger Biopharmaceuticals Inc. (San Carlos, Calif.) will acquire Celladon Corp. (NASDAQ:CLDN) through a reverse merger. Eiger President and CEO David Cory will lead the combined company, which will be named Eiger and will trade on...
08:00 , Feb 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease ...